Scientific Advisory Board

Dr. David Kingston MB BS, BPharm, BSc


David has many years’ experience in the pharmaceutical industry and worked in many therapeutic areas including oncology, virology, diabetes, cardiovascular, CNS and transplant amongst others.

As Medical Director of Roche Australia he has been involved in all product lifecycle phases from phase 1 to 4 including clinical development, regulatory, PBS listing and medical affairs for more than 40 new products.  Also, as Head of Clinical Development for the Asia pacific region he has been involved in establishing units in many Asian countries, planning studies in the region and representing the region on the global leadership team.

David has a MB BS, BPharm and BSc (pharmacology). He also has completed Advanced Management Programs at Macquarie University, Sydney and Columbia University, New York.  In the past few years he has worked as a consultant to a number of small start-up companies and CROs.  He also lectures in the post graduate Pharmaceutical Medicine and Drug Development program of the University of NSW.

Dr. Richard Pestell AO, MD, PhD, MBA, FACP, FRACP


Originally from Perth, Australia, Dr Pestell holds a medical degree from the University of Western Australia, and a Ph.D. from the University of Melbourne, Howard Florey Institute (1991). He conducted clinical training in oncology and endocrinology and was inducted as a Fellow of the Royal Australian College of Physicians.

Dr Pestell's postdoctoral research at the Harvard School of Medicine and Massachusetts General Hospital (1991-1993) and Assistant Professor at Northwestern University in Chicago with Dr. Larry Jameson focused on endocrine oncology (1993-1995). He became Associate then full  Professor at Albert Einstein College of Medicine in New York (1996-2002), then Tenured Endowed Professor and Chairman of the Department of Oncology, Director of the Lombardi Comprehensive Cancer Center, and Associate Vice President of the Medical Center, Georgetown University, Washington DC (2002-2005).

From 2005-2016 he was Director of the Sidney Kimmel Cancer Center and then Executive Vice President, Thomas Jefferson University.  He has received many awards for his research discoveries including elected membership to ASCI (American Society of Clinical Investigation), Elected Member, Royal Society of Medicine, the RD Wright Medallion, Elected Fellow, American Association for the Advancement of Science, the Eric Susman Prize in Medicine, Advance Global Australian Award (Biotechnology), a Doctor of Medical Sciences, Honoris Causa, from the University of Melbourne, and awards from Susan G. Komen (Light of Life award, Jamie Brooke Lieberman Award). He founded two biotechnology companies and has several issued patents in biotechnology, diagnostics and cancer therapeutics.



Dr. Gane is Professor of Medicine at the University of Auckland, New Zealand, Hepatologist and Deputy Director of the New Zealand Liver Unit at Auckland City Hospital.

Dr. Gane trained in hepatology at the Institute of Liver Studies, King’s College School of Medicine, London, where he completed his MD on the pathogenesis of hepatitis C-related liver injury.  In 1998, Dr. Gane was appointed as Chief Physician for the first New Zealand Liver Unit at Auckland City Hospital, which provides a national transplant and HCC programme and regional hepatitis services. Dr Gane chairs the Ministry of Health HepC Implementation committee.

Dr. Gane is an investigator for many international clinical trials with particular interest in early phase development of new therapies against nonalcoholic fatty liver disease and direct acting antiviral therapies for chronic hepatitis C and hepatitis B.  He has published more than 300 papers in peer-reviewed journals including The Lancet and The New England Journal of Medicine.

Dr Gane is a member of APASL and AASLD and is a Fellow of the Royal Society of New Zealand.

In 2011, Dr. Gane was awarded Member of the Order of New Zealand for Services to Medicine and in 2017, was the New Zealand Innovator of the Year for his work towards HCV elimination in New Zealand.

Dr. Jordan Moon


Dr. Moon is the Executive Director of Research and Education at ImpediMed Inc., a medical device company focusing on fluid and tissue changes in clinical and non-clinical populations. He received his PhD in Exercise Physiology from The University of Oklahoma and has served as an Associate Professor and Program Director for Sports Management and Sports & Health Sciences at American Public University and American Military University as well as serving as the Department Chair of Sports Exercise Science and Human Performance Laboratory Director at the United States Sports Academy.

Outside of academia, he directed the building and development of the MusclePharm Sports Science Institute and oversaw all clinical trials. With MusclePharm and Impedimed, he has directed and funded over 45 clinical trials and as a laboratory director has acquired over 20 grants. Throughout the last decade, Dr. Moon has presented over 50 lectures at multiple scientific conferences and events both nationally and internationally and has published more than 140 research articles and abstracts in dozens of journals along with writing a book chapter and publishing a book in the areas of sports nutrition, supplements, exercise science, body composition, body water, and changes regarding age and fitness level.